Impact of nanosystems in Staphylococcus aureus biofilms treatment

ABSTRACT Staphylococcus aureus (S. aureus) is considered by the World Health Organization as a high priority pathogen for which new therapies are needed. This is particularly important for biofilm implant-associated infections once the only available treatment option implies a surgical procedure com...

Full description

Saved in:
Bibliographic Details
Published in:FEMS microbiology reviews 2019-11, Vol.43 (6), p.622-641
Main Authors: Pinto, Rita M, Lopes-de-Campos, Daniela, Martins, M Cristina L, Van Dijck, Patrick, Nunes, Cláudia, Reis, Salette
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Antibiotics
Biofilms
Biofilms - drug effects
Care and treatment
Equipment and Supplies - microbiology
Health services
Humans
Mice
Microbial Sensitivity Tests
Nanostructures
Nanotechnology
Nanotechnology - methods
Prosthesis-Related Infections - drug therapy
Review
Staphylococcal infections
Staphylococcal Infections - drug therapy
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Staphylococcus aureus (S. aureus) is considered by the World Health Organization as a high priority pathogen for which new therapies are needed. This is particularly important for biofilm implant-associated infections once the only available treatment option implies a surgical procedure combined with antibiotic therapy. Consequently, these infections represent an economic burden for Healthcare Systems. A new strategy has emerged to tackle this problem: for small bugs, small particles. Here, we describe how nanotechnology-based systems have been studied to treat S. aureus biofilms. Their features, drawbacks and potentialities to impact the treatment of these infections are highlighted. Furthermore, we also outline biofilm models and assays required for preclinical validation of those nanosystems to smooth the process of clinical translation. Staphylococcus aureus biofilms are a major cause for implant-associated infections. The lack of an effective treatment and the escalating numbers of antibiotic-resistance events are prompting the research toward alternative nano-based strategies.
ISSN:1574-6976
0168-6445
1574-6976
DOI:10.1093/femsre/fuz021